Hippocampal GFAP in aging: Associations with AD and LATE-NC pathologies and cognitive decline in older adults.
Brain inflammation markers predict cognitive decline across multiple dementia types, expanding our understanding beyond Alzheimer's disease alone.
Post-mortem hippocampal GFAP burden in Rush ADRC cohorts is specifically linked to LATE-NC and tangle pathology rather than amyloid-β, and independently predicts faster cognitive decline across multiple cognitive domains. This supports hippocampal GFAP as a biomarker bridging multiple dementia pathologies beyond classic Alzheimer's disease.
What the study was
- Study design
- Neuropathological cohort study with regression/mixed-effect models
- Population
- Older adults from Rush Alzheimer's Disease Center cohorts
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Alzheimers Dement
Why it surfaced
Extends GFAP as a multi-pathology aging/dementia biomarker beyond plasma into brain tissue correlates, with links to LATE-NC and independent cognitive decline prediction. Rush ADRC is a strong and trusted cohort.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.